Lead Product(s) : Obinutuzumab,Chlorambucil
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Nippon Shinyaku
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gazyva (obinutuzumab), is a glycoengineered type II anti-CD20 monoclonal antibody designed to bind to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells.
Product Name : Gazyva
Product Type : Antibody
Upfront Cash : Inapplicable
December 23, 2022
Lead Product(s) : Obinutuzumab,Chlorambucil
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Nippon Shinyaku
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
